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Abstract: Adverse outcomes following virus-associated disease in patients receiving allogeneic
haematopoietic stem cell transplantation (HSCT) have encouraged strategies to control viral
reactivation in immunosuppressed patients. However, despite timely treatment with antiviral
medication, some viral infections remain refractory to treatment, which hampers outcomes after
HSCT, and are responsible for a high proportion of transplant-related morbidity and mortality.
Adoptive transfer of donor-derived lymphocytes aims to improve cellular immunity and to prevent
or treat viral diseases after HSCT. Early reports described the feasibility of transferring nonspecific
lymphocytes from donors, which led to the development of cell therapy approaches based on
virus-specific T cells, allowing a targeted treatment of infections, while limiting adverse events
such as graft versus host disease (GvHD). Both expansion and direct selection techniques have
yielded comparable results in terms of efficacy (around 70–80%), but efficacy is difficult to predict
for individual cases. Generating bespoke products for each donor–recipient pair can be expensive,
and there remains the major obstacle of generating products from seronegative or poorly responsive
donors. More recent studies have focused on the feasibility of collecting and infusing partially
matched third-party virus-specific T cells, reporting response rates of 60–70%. Future development of
this approach will involve the broadening of applicability to multiple viruses, the optimization
and cost-control of manufacturing, larger multicentred efficacy trials, and finally the creation
of cell banks that can provide prompt access to virus-specific cellular product. The aim of this
review is to summarise present knowledge on adoptive T cell manufacturing, efficacy and potential
future developments.
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1. Introduction
Haematopoietic stem cell transplantation (HSCT) represents an important curative option for
a large group of malignant (mainly leukaemias and lymphomas) and nonmalignant disorders
(e.g., primary immunodeficiencies and metabolic diseases). However, outcomes can be hampered
by a wide spectrum of transplant-related complications including viral infections, which are a major
cause of morbidity and mortality in transplanted patients [1]. Accurate incidences of viral infections in
transplant settings are not reported consistently since differences in sample analysis (e.g., whole blood
versus plasma) [2] or different viral load cut-offs for positivity, can lead to heterogeneous results [3].
Although pharmacological therapies are available to treat viral infections, many are ineffective due
in part to drug resistance, or having to cease therapy due to drug-related toxicities. Furthermore,
prolonged therapy is expensive. For these reasons, virus-specific T cells (VsTs), mainly cytotoxic T
lymphocytes (CTLs), have been increasingly investigated as a treatment option for refractory viral
infections in transplanted patients.
Different strategies for VsT manufacture have been employed to improve viral specificity of T
cells towards single or multiple viruses, including methods of cell selection or in-vitro stimulation,
choice of cell source, and HLA (human leukocyte antigen) matching. In this review, we illustrate the
relevant differences in approaches to adoptive cell therapy using lymphocytes, focusing on factors
influencing the efficacy of CTLs, and overview the latest advances and possible future developments
of antiviral T-cell therapy.
2. Refractory Viral Infections Following HSCT
Preemptive therapy for viral infections in transplanted patients aims to treat subclinical viral
reactivation before clinical manifestations appear, since during the immunocompromised state of
transplanted patients there is insufficient host immunity to control viral replication. The first-line
approaches to viral infections comprise tapering of immunosuppression, and antiviral drug therapy.
However, patients may not respond due to the lack of immune reconstitution, viral drug resistance or
drug toxicity. Patients receiving serotherapy as part of conditioning (to deplete T cells), or steroids
for treatment of GvHD, are at higher risk of viral reactivation. Prophylaxis against GvHD with
T cell-depleting alemtuzumab can lead to a profound lymphopenia that raises the risk of viral
infection. Data on the impact of HLA matching show that mismatched transplants are not usually
associated with a higher susceptibility to infections [4]. Routine monitoring of viral reactivation in the
post-transplant setting usually includes molecular detection of viral DNA of the three most frequent
viruses responsible for refractory infections, namely human adenovirus (AdV), cytomegalovirus (CMV)
and Epstein–Barr virus (EBV). Data on incidence of viral reactivation, viral disease, standard treatment
and rate of response are summarised in Table 1. AdV-associated disease usually occurs within the
first two months post-transplant. Although some patients remain asymptomatic and clear the virus
spontaneously, others can present with rapid progression to fatal multiorgan failure. The incidence of
AdV viremia following HSCT is higher in paediatric patients, with a significantly higher mortality for
patients developing AdV disease [5]. Clinical manifestations include haemorrhagic enteritis or cystitis,
pneumonia, hepatitis, encephalitis and multiorgan failure [6]. Cidofovir is currently the recommended
first-line drug for pre-emptive therapy of AdV infection [7], although outcome is usually hampered by
T-cell lymphocytopenia and renal toxicity. However, the evidence for reducing mortality is inconsistent,
with similar mortality rates (~ 20%) being reported in patients receiving or not receiving pre-emptive
therapy [8,9]. For these reasons, new pharmacological approaches have been explored, leading to the
development of new molecules. Brincidofovir has been recently adopted for refractory AdV infections
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with good rates of response, although data remain scarce, especially in children [10]. Moreover, this
drug is also associated with some organ toxicity, mainly related to the gastrointestinal tract. In a recent
retrospective study, brincidofovir appeared to reduce adenoviral load more rapidly than cidofovir, and
did so in the absence of lymphocyte recovery [11]. Prospective studies are underway to assess the
effect of brincidofovir on adenoviral-related mortality following HSCT (AdAPT).
Table 1. Reported incidence of AdV, CMV and EBV post-transplant reactivation in peripheral blood,
and disease-specific pharmacological treatment and rate of treatment response in children and adults
undergoing haematopoietic stem cell transplantation.
Patients Viremia Viral Disease Treatment Response Rate
AdV
Children 15–30% 6–11%
Cidofovir, brincidofovir 60–80%Adults 6–15% 2%
CMV
Children 15–20% 4% Gancyclovir, foscarnet, valgancyclovir 70–80%Adults 39% 13%
EBV
Children 11% 1–7%
Rituximab 60–70%Adults 22% 1–3%
Cytomegalovirus reactivation following HSCT can occur in up to 40% of transplanted patients [12],
although pre-emptive pharmacological approaches reduce incidence of CMV disease. Gastrointestinal
and pulmonary involvement are the main clinical presentations, but evolution to disseminated disease
can occur [13]. Several drugs can be used to tackle CMV reactivation. The best established is
ganciclovir, although associated myelotoxicity precludes its use as first-line therapy in the early
phases of transplants. Foscarnet is generally the next alternative to ganciclovir for CMV infections at
this stage, although it is associated with a significant risk of renal toxicity. There is some early data on
the use of oral valganciclovir in the bone marrow transplant setting, but myelotoxicity may still be a
problem [14,15]. Akin to bacterial resistance to antibiotic therapy, recent next-generation sequencing
studies are now highlighting the role of CMV genome mutations resulting in drug-resistant virus
strains [13,16].
Epstein–Barr virus (EBV) reactivation after HSCT can lead to clonal proliferation of CD20+ B cells,
potentially causing lymphoproliferative disease. The increased use of anti-CD20 monoclonal antibody
(Rituximab) has significantly reduced the incidence and mortality of EBV-driven post-transplant
lymphoproliferative disease (PTLD), especially in children [17]. However, although anti-CD20 therapy
can lead to excellent response rates as a pre-emptive strategy, efficacy as treatment of PTLD is around
60% [18]. Indeed, occasional patients are refractory to Rituximab, and require consideration for
chemotherapy (e.g., CHOP) or adoptive CTLs.
Human herpes virus 6 (HHV6) can also cause occasional severe organ failure (lung, liver, CNS)
and, rarely, fatal outcome in post-transplant patients. Viral reactivation needs to be distinguished
from chromosomal integration. Risk factors for viral reactivation include delayed T-cell reconstitution,
co-reactivation with other viruses, and use of cord blood as a source of stem cells [19], although
the exact prevalence of HHV6 reactivation is not well documented since it is not part of the routine
viral monitoring in transplanted patients, and may be found in the absence of any associated clinical
features. Therapy with ganciclovir, foscarnet and cidofovir have been variously used to tackle HHV6
reactivation, but there is no consensus on therapeutic, prophylactic or preventive strategies.
Hemorrhagic cystitis due to BK virus infection is a painful and difficult condition to treat, and
can hamper the outcome of HSCT. Although some authors reported that cidofovir either systemic or
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intravesical can improve or reduce BK viremia or viruria, there are insufficient data to recommend its
use as standard treatment.
Progressive multifocal leukoencephalopathy (PML) is a severe potentially fatal complication
caused by JC virus reactivation, which can occur usually in late post-transplant phases (11–60 months).
The diagnosis represents a significant challenge for clinicians as there are no specific treatments to
prevent or reduce progression. Cidofovir, IL-2, cytarabine and IVIG have been variably used, but there
is little evidence to suggest that such therapies prevent fatal outcome, which eventually occurs in a
considerable proportion of patients.
Antiviral responses are mainly related to the patients’ adaptive immune recovery, which is unlikely
to have recovered in the early days after transplantation [20]. Post-transplant immune reconstitution
can be influenced by several variables, mainly related to transplant characteristics. Use of in vitro or
in vivo T cell depletion is universally accepted as a main strategy to avoid graft rejection and reduce
graft versus host disease for transplants from unrelated or mismatched family donors. However,
this results in a consistent delay in recovery from profound lymphopenia. Anti-thymocyte globulin
(ATG), derived from either rabbit or horse sera, specifically targets T cells, while anti-CD52 monoclonal
antibody (Alemtuzumab) depletes T and B lymphocytes as well as NK cells. The risk of viral infections
is generally higher using Alemtuzumab due to delayed lymphocyte recovery, when compared to
ATG [21], although timing and dosing of each antibody will play a major role.
HLA matching can also impact on the rapidity of lymphocyte recovery post-transplant, and a
slower T cell recovery usually occurs after haploidentical transplantation [22]. The stem cell source is
also responsible for the speed of lymphocyte recovery. Peripheral blood or bone marrow stem cells
generally give a faster increase in the number of T and B lymphocytes, as compared to cord blood.
However, omission of in vivo T cell depletion with ATG in cord blood unit recipients leads to a unique
and rapid expansion of CD4+ lymphocytes [23].
Viral strains can show mutation in viral DNA that can confer resistance to pharmacological
treatment, although most refractory viral infections do not show a specific pattern of DNA mutations,
and no consensus on patient selection for genotypic drug resistance testing is currently available [24].
3. From DLI to Virus-Specific T Cells and Beyond
Therapy with ex vivo-selected lymphocytes to treat viral infections after HSCT was originally
based on infusion of nonspecific donor-derived lymphocytes (donor lymphocyte infusions:
DLIs). The pioneering studies of this approach proved that restoring antiviral immunity
in immunocompromised hosts was feasible and could cure refractory viral infections [25,26].
Good response rates were first observed in patients treated for EBV-driven post-transplant
lymphoproliferative disease (PTLD) [25]. However, the broad T cell receptor repertoire of infused T
cells, not specifically committed to antiviral activity, but also targeting host MHC, led to development
or exacerbation of GVHD. This seemed to limit the use of DLI in transplanted patients, but refinement
of the cellular product, through depletion of allo-reactive T cells [27,28], was implemented in order to
reduce the risk of GVHD, yet preserving antiviral activity.
Further development of cellular therapies for viral infections focused on the specificities of T
cells for different viruses, aiming to achieve higher response rates [29,30]. The first and most widely
used protocols to develop virus-specific T cells (VSTs) were based on ex vivo generation and in vitro
expansion of T cells, leading to a final product comprising polyclonal T cells (recognizing different
immunogenic viral antigens), with the manufacture of substantial numbers of cells from a relatively
small volume of blood. More importantly, one of the main advantages of ex vivo differentiation of
VSTs is that it could overcome the potential obstacle represented by paucity of specific immunity for
the virus in the donor immune system. However, this approach can require a long production time
(from a minimum of 13 days and up to 3 months), which can limit the use of ex vivo-expanded VSTs in
critically ill patients [31,32].
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A more rapid way to obtain VSTs from the donor is direct selection of specific T cells, using
either (1) viral peptide multimers conjugated to magnetic beads, to select highly pure cytotoxic T cells,
or (2) stimulation with viral peptides followed by IFN-gamma capture assay with magnetic beads,
which allows selection of both CD4+ and CD8+ virus-specific T cells. CD4+ T cell help is considered
essential to induce a sustained immune response, whereas CD8+ T cells are responsible for the rapid
antiviral effects. Therefore, a cellular product containing both CD4+ and CD8+ T cells is thought
most likely to rapidly impart sustained protective immunity. These two approaches enable rapid
production of cellular products specifically directed against viruses [33,34], although these techniques
are mainly limited to donors that have already developed a specific immunological memory for the
virus. Moreover, a large volume of donor blood (100–500 mL) is usually needed to obtain clinically
useful cell doses. Furthermore, in vitro activation or expansion can exhaust the resulting T cells.
There have been no large controlled prospective randomized trials using good manufacturing
practice (GMP) processes investigating the efficacy of VSTs obtained by either exvivo expansion
or direct selection, though there have been many small-scale studies (Table 2). However, there
are now plans for a multinational, placebo-controlled, Phase-III clinical trial (TRACE (transfer of
multivirus-specific T cells), involving some of the authors, led by T.F.) which will aim to generate
evidence so that adoptive transfer of virus-specific T cells can be included into evidence-based
treatment guidelines to become a standard treatment for refractory viral infections post-HSCT.
Table 2. Largest published clinical trials for treatment and prevention of viral reactivation after HSCT
using donor-derived single-virus adaptive therapy, using either ex vivo expansion or direct selection.
Patients (n) Population Viral Infection VST Stimulated or Isolated by Citation
Ex-Vivo Expanded
113 Adults/Children EBV LBC Heslop, 2010 [35]
50 Adults/Children CMV Mo-DC pp65-restricted Blyth, 2013 [36]
8 Children ADV Multi-peptides AdV5 Ip, 2018 [37]
Direct Selection
10 Adults/Children EBV IFN-γ capture Icheva, 2013 [38]
18 Unknown CMV IFN-γ capture Peggs, 2011 [34]
30 Adults/Children ADV IFN-γ capture Feucht, 2015 [39]
Abbreviations: LBC: lymphoblastoid cells; IFN: interferon; Mo-DC: monocyte-derived dendritic cells.
Manufacturing virus-specific T cells is based upon knowledge of viral antigen immunogenicity.
While some viral antigens capable of inducing an immunological response are well characterized
(e.g., pp65 for CMV, EBNA2–6 for EBV), this is less understood for other viruses, such as AdV, HHV6
and BK virus. Dedicated BKV-specific T cell products manufactured using peptides and rapid antigen
capture based on multimers have been described [40,41]. There is only one report on the use of ex
vivo-specific CTLs for JC PML [42], which showed the proof of principle of this approach. Currently, a
National Institutes of Health (NIH) Phase I study (NCT02694783) is recruiting patients for use of JC
virus-specific CTLs in transplanted patients with PML.
Post-transplant management of viral infections can be particularly challenging in the presence of
multiple refractory viral infections, and in order to obtain control of multiple infections with adoptive
T cells, patients can be treated with multivirus-specific T cell therapy [32] (Table 3). The rationale
is based on recognition by CTLs of immunodominant viral proteins derived from CMV, EBV and
AdV simultaneously. This approach could incorporate targeting other viruses, such as HHV6 and BK
virus [43]. The different immunogenic potentials of viral antigens could lead to antigen competition
during in vitro manufacturing of CTLs, resulting in loss of specificity towards less immunogenic viral
epitopes (such as AdV) in the final product. However, it has been shown that low frequencies of
infused donor-derived CTLs can sufficiently expand in vivo with clinical benefit [44].
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Table 3. Largest published clinical trials for treatment and prevention of viral reactivation after HSCT
using donor-derived multiple-virus adaptive therapy.
Patients (n) Population Viral Specificity VST Stimulated by Citation
13 Children EBV/ADV LBCs transduced withADV vector Leen, 2009 [45]
15 Adults/Children ADV/CMV/EBV LBCs transduced with ADVvector encoding CMVpp65 Leen, 2006 [32]
10 Adults ADV/CMV/EBV/VZV
Mo-DC transduced with ADV
vector encoding CMVpp65,
EBNA1, VZV vaccine
Ma, 2015 [46]
11 Adults/Children ADV/CMV/EBV/BKV/HHV6
Pepmixes of
immunodominant antigens
Papadopulou,
2014 [43]
Abbreviations: LBC: lymphoblastoid cells; Mo-DC: monocyte-derived dendritic cells; VZV: Varicella–Zoster virus;
EBNA1: Epstein–Barr nuclear antigen 1.
4. Efficacy of Donor-Derived T Cells: Promising Potential and Pitfalls
Since the first clinical trials for EBV, CMV and AdV [47,48], the use of adoptive T cell therapy
has rapidly grown, with high rates of response reported for VSTs. There has been a lack of large
prospective multicenter clinical trials, and efficacy of virus-specific adoptive therapy has been difficult
to quantify due to variations in manufacturing technology and patients treated. Indeed, endpoints of
reported studies may differ (i.e., reduction in viral load, viral clearance, mortality), and differences
in terms of efficacy between different strategies of manufacturing cannot be easily elucidated or
reconciled. However, results have been consistent on the use of anti-CMV T cells as prophylaxis
showing a beneficial effect on the occurrence of viral reactivation after HSCT [36,49], being significantly
lower than in control groups. Clearance of CMV in refractory infections is expected in around
70–80% of patients [50–52]. Similarly, efficacy of anti-AdV and anti-EBV VSTs in terms of viral load
clearance/reduction has been reported to be around 70% [39,53], and CTLs for EBV and AdV infection
have been proved to be an effective prophylactic/pre-emptive therapy or treatment for PTLD and
AdV reactivation post-HSCT. Especially in EBV-PTLD, CTLs are considered as second-line therapy
after Rituximab [53]. Interestingly, despite the potential risk of inducing GvHD, its incidence was not
increased when CTL recipients were compared with patients that did not received T cell infusions.
Most authors have reported only minor-grade (I–II) GvHD, or minimal worsening of previous GVHD,
associated with infusion of antigen-specific CTL, reflecting the high specificity of these cellular products
and the efficiency of negative selection of alloreactive T cells. Although the cumulative incidence of
acute and chronic GvHD did not differ from a control cohort [36], occasional severe (> grade II) acute
GvHD has been reported in isolated cases [46]. Uses of selective CTLs to treat BK virus and JC virus
reactivation have been reported as case reports, and no conclusions can be drawn on the efficacy of this
approach [42]. The specificity of these products has also been demonstrated using an in vitro model
of GvHD and anti-CMV T cells, which only demonstrated a grade I–II histopathological reaction on
patient skin following patient–donor mixed lymphocyte reactions [54].
There are no accepted predictive markers for response; peripheral blood viral load is not a reliable
parameter in the early stages, since EBV DNA can be undetectable despite ongoing lymphoproliferative
disease within organs, and, conversely, CMV and AdV DNA can show transient surges early after T
cell infusions, possibly due to the cytolysis of infected cells.
Positive outcomes for refractory viral infection treated with virus-specific T cells from the HSCT
donor can be hampered by several factors. One of the main variables influencing the curative potential
of CTLs is appropriate timing for infusion. Different studies reported a significantly lower success
rate when CTLs were administered in patients with organ damage or multiorgan involvement [34,46],
although viral load clearance and positive outcome has been reported even in cases of severely ill
patients (i.e., CMV encephalitis). Mortality due to viral infection is usually extremely high in patients
that fail to respond to adoptive therapy [51], probably reflecting the advanced stage of disease at the
time of cellular therapy. On the other hand, some authors suggest that in theory, infusion of CTLs may
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initially increase inflammation in involved tissues leading to additional organ damage and death [55],
despite viral clearance. For these reasons, although an appropriate window of treatment cannot be
defined, adoptive therapy should probably be used in the early phases of viral disease.
CTL effect on viral replication is mainly related to appropriate expansion of infused cells, which
generally occurs within 2–4 weeks, but has been reported up to 16 weeks after infusion [51]. However,
it can be difficult to predict the timing of adoptive T cell expansion due to several variables relating to
the patient and transplant characteristics: initial viral load; ongoing immunosuppression; and invivo T
cell depletion, conditioning, and persistence of serotherapy [39]. Theoretically, efficacy of CTLs could
be hampered by use of concomitant immunosuppression, as is usual at this time point in the transplant
setting. Most investigators prefer prednisone to be at a dose of <1 mg/kg at the time of CTL infusion,
however, in some studies, patients receiving steroids and/or other immunosuppressive drugs showed
similar response rates to patients without ongoing immunosuppression [53].
Persistence of cells is not evenly reported by authors, and possible differences could be
related to manufacturing protocols, and immunosuppressive drugs used in the context of GvHD.
Although infused CTLs have been detected more than eight years after the infusion [35], viral clearance
is mainly related to early expansion of infused CTLs, more than the long-term persistence of adoptive
cells in peripheral blood. Accordingly, the phenotypic composition of adoptive T cells can influence
virus-specific T cell expansion. Terminally differentiated T cells show a lower persistence and efficacy
when compared to less differentiated cells [56].
A minimum infusion dose is not easily determinable, since even a few cells, with large expansion
potential, can lead to sustained antiviral immunity. It is also noteworthy that nonresponder patients
who did not clear or significantly reduce the blood viral load can show appropriate cell expansion [57],
again suggesting that outcomes after CTLs are not easily predictable. Interestingly, no significant
differences in efficacy have been demonstrated with different CTL doses or administration schedules,
even when compared to DLIs. Despite a narrow range of administered doses (1× 104/kg−2 × 106/kg),
even at the lowest of these doses, viral load clearance has been achieved, with a concomitant expansion
of transferred T cells [35,53].
Treatment failures have been correlated to the lack of recognition of the target by infused CTLs [53].
T cells from the donor are sensitized in vitro to recognize specific HLA-restricted viral antigens. In the
case of EBV-PTLD, when CTLs are sensitized using an exogenous strain, they may not be able to
recognize the endogenous patient strain, which can present different antigen–HLA combinations to
T cells. This may occur when mutation of the viral DNA leads to the lack of expression of certain
epitopes or lack or recognition of specific HLA antigens by T cell receptor of donor T cells [53,58].
In selected scenarios, therefore, some patients could benefit from a personalized selection of CTLs
derived from a third party that are able to recognize that specific HLA phenotype.
5. Third Party CTLs
Donor-derived VST infusions are not always feasible in clinical practice due to the lack
of specific immunity of donor cells (e.g., high-risk patients: CMV-seropositive receiving HSCT
from CMV-seronegative donor), or the availability of the donor (e.g., patients undergoing UCB
transplantation), and the time required for manufacture of the cellular product might be too prolonged
to deal with the rapid clinical evolution of viral infection. Moreover, treatment failure can occur due to
specific HLA restriction of donor-derived CTLs that are unable to recognize viral epitopes generated
by viral DNA mutation and presented by a different HLA complex. In this scenario, use of more
specific HLA restriction of T cells could correctly recognize viral antigens and clear the virus [53].
Ideally, the use of selected T cells with higher grades of specificity for particular HLA types could add
additional benefit in terms of viral clearance, minimizing the risk of treatment failure.
The encouraging results following infusion of viral-specific T cells in solid organ-transplanted
patients [59] suggested that third-party CTLs could be effectively used also in the setting of HSCT [53].
After a few initial reports [60,61] (Figure 1), demonstrating efficacy of third-party virus-specific T cells
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in HSCT patients, banks of third-party CTLs were developed in order to store specific antiviral T cell
products that could be immediately available in the case of refractory infections. However, there are
potential drawbacks to this approach: (1) partially matched cells might be recognized by the host
immune system leading to rejection of CTLs; (2) the risk of alloreactive phenomena against recipient
cells. Although few centers have implemented an “off-the-shelf” program of CTLs for HSCT recipients,
and no randomized trials have been conducted yet, the published results suggest an overall response
rate around 60–80% [62,63], both as prophylaxis and therapy, with a relatively low burden of severe
complications (GvHD > grade II), similarly to donor-derived CTLs. This approach may be clinically
beneficial in the early phases of post-transplant refractory infection, but lack of persistence of third
party CTLs represents a concern, and there are still few data on long-term effects on viral clearance and
specific immune reconstitution. Third-party CTLs have been detected up to 90 days after infusion, but
persistence is expected to be shorter. Intriguingly, viral clearance is usually sustained, possibly related
to specific antiviral immunity recovery following CTL infusion [63]. As mentioned above, third-party
CTLs could also represent a promising alternative in patients who fail to respond to donor-derived
CTLs and present viral genome mutations that lead to specific antigen–HLA combinations that are
unrecognized by donor T cells. A more complete understanding of the mechanism of viral recognition
by CTLs could lead to a personalized approach to adoptive cell therapy by matching the recipient
HLA–epitope combination with the more appropriate HLA-restricted CTLs.
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6. Conclusions
Viral infections after HSCT can be challenging for clinicians, and are a major cause of morbidity
and mortality, especially in high-risk patients. Infusion of adoptive VSTs can tackle viral replication
and restore antiviral immunity in patients not responding to antiviral drugs. The expected response
rates are between 50–90%, with different manufacturing techniques, and even in the HLA partially
matched setting, antiviral efficacy is reported around 50–70%. Toxicity is usually temporary and easily
controlled, occurring only in a small proportion of patients. Further challenges might be addressed by
broadening applicability to all transplanted patients (i.e., patients with active GvHD) and reducing
the time to access cellular products using VST cell banks. Moreover, transplant-related mortality
also arises from respiratory virus infections, JC and BK virus, and other viral infections that lack an
effective antiviral treatment. Therefore, cellular products that can also target these viruses are required.
Future challenges of adoptive therapies will include broadening applicability to different categories of
patients, and the better definition of patient-oriented strategies.
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